Chlorothiazide (injection)

Chlorothiazide (injection)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Chlorothiazide (injection) is a thiazide diuretic that is FDA approved for the treatment of edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Common adverse reactions include photosensitivity, hyperglycemia, hyperuricemia, diarrhea, loss of appetite, nausea, vomiting, and dizziness.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Edema

• Dosing Information

• 500 to 1000 mg PO/IV qd–bid
• Chlorothiazide for injection should be reserved for patients unable to take oral medication or for emergency situations. Use the smallest dosage necessary to achieve the required response.
• Many patients with edema respond to intermittent therapy, i.e., administration on alternate days or on three to five days each week. With an intermittent schedule, excessive response and the resulting undesirable electrolyte imbalance are less likely to occur.

Hypertension

• Dosing Information

• 500 to 1000 mg PO as once daily or in divided doses; up to 2000 mg a day in divided doses
• Chlorothiazide for injection should be reserved for patients unable to take oral medication or for emergency situations. Use the smallest dosage necessary to achieve the required response.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Chlorothiazide (injection) in adult patients.

Non–Guideline-Supported Use

Hypercalciuria

• Dosing Information

• 20 mg/kg/day

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Safety and effectiveness of chlorothiazide in pediatric patients have not been established.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Chlorothiazide (injection) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Chlorothiazide (injection) in pediatric patients.

Contraindications

• Anuria
• Hypersensitivity to any component of this product or to other sulfonamide-derived drugs.

Warnings

Intravenous Use

• Intravenous use in infants and children has been limited and is not generally recommended.

• Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

• Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

• Thiazides may add to or potentiate the action of other antihypertensive drugs.

• Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma.

• The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

• Lithium generally should not be given with diuretics.

Precautions

General

• All patients receiving diuretic therapy should be observed for evidence of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.

• Hypokalemia may develop especially with brisk diuresis, when severe cirrhosis is present or after prolonged therapy.

• Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia may cause cardiac arrhythmias and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). Hypokalemia may be avoided or treated by use of potassium-sparing diuretics or potassium supplements such as foods with a high potassium content.

• Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease), chloride replacement may be required in the treatment of metabolic alkalosis.

• Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the hyponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

• Hyperuricemia may occur or acute gout may be precipitated in certain patients receiving thiazides.

• In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required.

• Hyperglycemia may occur with thiazide diuretics. Thus latent diabetes mellitus may become manifest during thiazide therapy.

• The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.

• If progressive renal impairment becomes evident, consider withholding or discontinuing diuretic therapy.

• Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia.

• Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.

• Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy.

Laboratory Tests

• Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be done at appropriate intervals.

Drug/Laboratory Test Interactions

• Thiazides should be discontinued before carrying out tests for parathyroid function.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Chlorothiazide (injection) in the drug label.

Postmarketing Experience

• Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.

• The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.

Body as a Whole

Weakness

Central Nervous System

Vertigo, paresthesias, dizziness, headache, restlessness

Cardiovascular

Hypotension including orthostatic hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs)

Gastrointestinal

Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia

Skin

Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia

Hematologic

Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia

Special Senses

Transient blurred vision, xanthopsia

Metabolic

Electrolyte imbalance, hyperglycemia, glycosuria, hyperuricemia

Renal

Renal failure, renal dysfunction, interstitial nephritis, hematuria (following intravenous use)

Urogenital

Impotence

Hypersensitivity

Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura

Miscellaneous

Muscle spasm

Drug Interactions

When given concurrently the following drugs may interact with thiazide diuretics.

• Alcohol, barbiturates, or narcotics

• Potentiation of orthostatic hypotension may occur.

• Antidiabetic drugs

• Dosage adjustment of the antidiabetic drug may be required.

• Other antihypertensive drugs

• Additive effect or potentiation

• Corticosteroids, ACTH

• Intensified electrolyte depletion, particularly hypokalemia

• Pressor amines (e.g., norepinephrine)

• Possible decreased response to pressor amines but not sufficient to preclude their use.

• Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)

• Possible increased responsiveness to the muscle relaxant.

• Lithium

• Generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide sodium.

• Non-steroidal Anti-inflammatory Drugs

• In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when chlorothiazide sodium and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

• Pregnancy Category C

• Teratogenic Effects

• Although reproduction studies performed with chlorothiazide doses of 50 mg/kg/day in rabbits, 60 mg/kg/day in rats and 500 mg/kg/day in mice revealed no external abnormalities of the fetus or impairment of growth and survival of the fetus due to chlorothiazide, such studies did not include complete examinations for visceral and skeletal abnormalities. It is not known whether chlorothiazide can cause fetal harm when administered to a pregnant woman; however, thiazides cross the placental barrier and appear in cord blood. Chlorothiazide should be used during pregnancy only if clearly needed.

• Nonteratogenic Effects

• Chlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.

Pregnancy Category (AUS):

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category C

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Chlorothiazide (injection) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Chlorothiazide (injection) during labor and delivery.

Nursing Mothers

• Because of the potential for serious adverse reactions in nursing infants from chlorothiazide sodium for injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

• Safety and effectiveness of chlorothiazide sodium for injection in pediatric patients have not been established.

Geriatic Use

• Clinical studies of chlorothiazide sodium for injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

• This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Gender

There is no FDA guidance on the use of Chlorothiazide (injection) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Chlorothiazide (injection) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Chlorothiazide (injection) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Chlorothiazide (injection) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Chlorothiazide (injection) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Chlorothiazide (injection) in patients who are immunocompromised.

Administration and Monitoring

Administration

• Oral
• Intravenous

• Chlorothiazide sodium for injection should be reserved for patients unable to take oral medication or for emergency situations.
• Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response.
• Intravenous use in infants and children has been limited and is not generally recommended.
• When medication can be taken orally, therapy with chlorothiazide tablets or oral suspension may be substituted for intravenous therapy, using the same dosage schedule as for the parenteral route.
• Chlorothiazide sodium for injection may be given slowly by direct intravenous injection or by intravenous infusion.
• Extravasation must be rigidly avoided. Do not give subcutaneously or intramuscularly.

Directions for Reconstitution

• Use aseptic technique. Because chlorothiazide sodium for injection contains no preservative, a fresh solution should be prepared immediately prior to each administration, and the unused portion should be discarded.

• Add 18 mL of Sterile Water for Injection to the vial to form an isotonic solution for intravenous injection. Never add less than 18 mL. When reconstituted with 18 mL of Sterile

• Water, the final concentration of intravenous chlorothiazide sodium is 28 mg/mL. The reconstituted solution is clear and essentially free from visible particles. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use whenever solution and container permit. The solution is compatible with dextrose or sodium chloride solutions for intravenous infusion. Avoid simultaneous administration of solutions of chlorothiazide with whole blood or its derivatives.

Monitoring

Renal Function

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

IV Compatibility

There is limited information regarding IV Compatibility of Chlorothiazide (injection) in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

• The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.

• The intravenous LD50 of chlorothiazide in the mouse is 1.1 g/kg.

Management

• In the event of overdosage, symptomatic and supportive measures should be employed. Correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment.

• The degree to which chlorothiazide sodium is removed by hemodialysis has not been established.

Chronic Overdose

There is limited information regarding Chronic Overdose of Chlorothiazide (injection) in the drug label.

Pharmacology

Mechanism of Action

There is limited information regarding Chlorothiazide (injection) Mechanism of Action in the drug label.

Structure

• Chlorothiazide sodium for injection, USP is a diuretic and antihypertensive. It is 6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide monosodium salt, and its structural formula is:

This image is provided by the National Library of Medicine.

• Chlorothiazide sodium for injection, USP is a sterile lyophilized white powder and is supplied in a vial containing: Chlorothiazide sodium equivalent to chlorothiazide 500 mg, and the inactive ingredient mannitol 250 mg with sodium hydroxide to adjust pH.

• Chlorothiazide is a diuretic and antihypertensive. It is 6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, and its structural formula is:

This image is provided by the National Library of Medicine.

• It is a white, or practically white, crystalline powder, which is very slightly soluble in water, but readily soluble in dilute aqueous sodium hydroxide. It is soluble in urine to the extent of about 150 mg per 100 mL at pH 7.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Chlorothiazide (injection) in the drug label.

Pharmacokinetics

• The mechanism of the antihypertensive effect of thiazides is unknown. Chlorothiazide does not usually affect normal blood pressure.

• Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy.

• Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.

• After oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours. Following intravenous use of chlorothiazide sodium, onset of the diuretic action occurs in 15 minutes and the maximal action in 30 minutes.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

• Carcinogenicity studies have not been conducted with chlorothiazide.

• Chlorothiazide was not mutagenic in vitro in the Ames microbial mutagen test (using a maximum concentration of 5 mg/plate and Salmonella typhimurium strains TA98 and TA100) and was not mutagenic and did not induce mitotic nondisjunction in diploid-strains of Aspergillus nidulans.

• Chlorothiazide had no adverse effects on fertility in female rats at doses up to 60 mg/kg/day and no adverse effects on fertility in male rats at doses up to 40 mg/kg/day. These doses are 1.5 and 1.0 times* the recommended maximum human dose, respectively, when compared on a body weight basis.

Clinical Studies

There is limited information regarding Clinical Studies of Chlorothiazide (injection) in the drug label.

How Supplied

• 500 mg/vial

• Packaged individually.

• This container closure is not made with natural rubber latex.

Storage

• Store lyophilized powder between 2° and 25°C (36° and 77°F).

• For single dose only. Use solution immediately after reconstitution (see DOSAGE AND ADMINISTRATION, Directions for Reconstitution). Discard unused portion of the reconstituted solution.

Storage

There is limited information regarding Chlorothiazide (injection) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Chlorothiazide (injection) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Chlorothiazide (injection) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Chlorothiazide (injection) in the drug label.

Precautions with Alcohol

• Hypotension including orthostatic hypotension may be aggravated by alcohol.

Brand Names

Diuril®

Look-Alike Drug Names

• N/A

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Chlorothiazide (injection)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Chlorothiazide (injection)
 |Label Name=Chlorothiazide03.jpeg

}}

{{#subobject:

 |Label Page=Chlorothiazide (injection)
 |Label Name=Chlorothiazide04.jpeg

}}

{{#subobject:

 |Label Page=Chlorothiazide (injection)
 |Label Name=Chlorothiazide05.jpeg

}}